TEXT SEARCHABLE DOCUMENT - 2009

Data Evaluation Report on the Reproductive Effects of BAS 800 H (Saflufenacil) on Northern Bobwhite (Colinus virginianus)

PMRA Submission Number: 2008-0430

EPA MRID Number: 47699904 PMRA Document ID: 1731030

Data Requirement:

PMRA Data Code **EPA DP Barcode**

9.6.3.1 D349851

OECD Data Point **EPA MRID**

IIA 8.1.4 47127915

EPA Guideline

OPPTS 850.2300

Test material:

BAS 800 H

Purity: 93.8%

Common name

Saflufenacil

Chemical name:

IUPAC: N'-{2-chloro-4-fluoro-5-[1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-

pyrimidin-1-yl]benzoyl}-N-isopropyl-N-methylsulfamide

CAS: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluoro-

N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide

CAS No.: 372137-35-4 Synonyms: None reported

Primary Reviewer: Christie E. Padova

Signature: Christie C. Padova

Staff Scientist, Dynamac Corporation

Date: 04/07/08

Secondary Reviewer: Teri S. Myers

Signature: Smpn
Date: 04/15/08

Date: 06/09/09

Pate: 06/09/09

Signature: Smpn

Africa

Senior Scientist, Cambridge Environmental Inc.

Primary Reviewer: Anita Pease

U.S. EPA, Senior Biologist

Secondary Reviewer: Janine Glaser

HC-PMRA-EAD

Secondary Reviewer: Farzad Jahromi DEWHA-APVMA

Date: 06/09/09

Company Code

BAZ

Active Code

SFF

Use Site Category

13 (terrestrial feed crops) and 14 (terrestrial food crops)

EPA PC Code

118203

CITATION: Zok, S. 2006. BAS 800 H - 1-Generation Reproduction Study on the Bobwhite Quail (Colinus virginianus) by Administration in the Diet. Unpublished study performed by Experimental Toxicology and Ecology, BASF Aktiengesellschaft, Ludwigshafen/Rhein, Germany. Laboratory Report No. 71W0414/015148. Study sponsored by BASF Corporation, Research Triangle Park, NC. Study initiated January 27, 2006 and submitted December 20, 2006.

DISCLAIMER: This document provides guidance for EPA and PMRA reviewers on how to complete a data evaluation record after reviewing a scientific study concerning the reproductive effects of a pesticide on avian species. It is not intended to prescribe conditions to any external party for conducting this study nor to establish absolute criteria regarding the assessment of whether the study is scientifically sound and whether the study satisfies any applicable data requirements. Reviewers are expected to review and to determine for each study, on a case-bycase basis, whether it is scientifically sound and provides sufficient information to satisfy applicable data



PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

requirements. Studies that fail to meet any of the conditions may be accepted, if appropriate; similarly, studies that meet all of the conditions may be rejected, if appropriate. In sum, the reviewer is to take into account the totality of factors related to the test methodology and results in determining the acceptability of the study.

EXECUTIVE SUMMARY

The one-generation reproductive toxicity of BAS 800 H (saflufenacil) to 16 pairs per level of *ca.* 5-month old northern bobwhite quail (*Colinus virginianus*) was assessed over 22 weeks. BAS 800 H was administered to the birds in the diet at nominal concentrations of 0 (control), 100, 300, and 1000 mg a.i./kg diet (adjusted for purity). Mean-measured concentrations were <10.0 (<LOQ, control), 96.0, 282, and 940 mg a.i./kg diet, respectively. Daily doses of the three treatment levels, based on measured concentrations of the technical substance, were 7.3, 20.7, and 70.1 mg a.i./kg bw, respectively.

The reviewer's analysis detected a significant treatment-related effect on hatchling body weight at the two highest treatment levels. No other biologically-significant treatment-related effects were observed on any adult or offspring parameter at any concentration level. Based on these results, the NOAEC and LOAEC were 96.0 and 282 mg a.i./kg.

This study is classified as ACCEPTABLE to U.S. EPA and as FULLY RELIABLE to PMRA and APVMA as it is scientifically sound and satisfies the guideline requirement for a northern bobwhite quail (*Colinus virginianus*) reproductive toxicity study.

Results Synopsis

Test Organism Size/Age (mean Weight): ca. 5-months old; 172.2-249.8 g (combined sexes)

NOAEC: 96.0 mg a.i./kg diet (7.3 mg a.i./kg bw) LOAEC: 282 mg a.i./kg diet (20.7 mg a.i./kg bw) Endpoint(s) Affected: hatchling body weight

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

I. MATERIALS AND METHODS

GUIDELINE FOLLOWED:

The study protocol was based on procedures outlined in the U.S. EPA *Pesticide Assessment Guidelines*, §71-4 (1982) taking into account the U.S. EPA Standard Evaluation Procedure (SEP), EPA 540/9-86-139 (1986); OECD Guideline No. 206 (1984); and U.S. EPA Ecological Effects Test Guidelines, OPPTS 850.2300 (1996). There were no deviations from OECD Guideline No. 205 noted. Deviations from OPPTS Guideline No. 850.2300 included:

- 1. The initial age of the test birds (ca. 5 months) was younger than recommended (at least 30 weeks old).
- 2. Cage size was significantly smaller than recommended. OPPTS recommends at least 5,000 cm² per bird. In this study, the floor space was only 1328 cm² per bird.

These deviations do not affect the scientific soundness of this study.

COMPLIANCE:

Signed and dated GLP, Quality Assurance and Data Confidentiality

statements were provided.

A. MATERIALS:

1. Test Material

BAS 800 H

Description:

Solid, light beige

Lot No./Batch No.:

COD-000515

Purity:

93.8%

Stability of compound under test conditions:

The stability of BAS 800 H was assessed in treated feed prepared at all treatment levels after 10 days of ambient storage (including 7 days in open feeders) during Week 1 (batch test diets were prepared 3 days prior to test initiation). Recoveries averaged 90.1-99.4% of nominal concentrations.

(OECD recommends water solubility, stability in water and light, pKa, Pow, and vapor pressure of test compound)

Storage conditions of

test chemicals:

Room temperature

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Physicochemical properties of saflufenacil.

Parameter	Values	Comments
Water solubility at 20°C	2.1 g/L	pH 7
Vapor pressure	4.5 x 10 ⁻¹⁵ Pa	20°C
UV absorption	272 nm	pH1/pH7
pKa	Neutral	Ambient pH
Kow	Log Pow 2.6	20°C

2. Test organism:

Table 1: Test organism.

Parameter	Details	Remarks <i>Criteria</i>
Species (common and scientific names):	Northern bobwhite quail (Colinus virginianus)	Birds were from the same hatch, and were phenotypically indistinguishable from wild birds.
		Recommended species include a wild waterfowl species, preferably the mallard (Anas platyrhynchos) or an upland game species, preferably the northern bobwhite (Colinus virginianus)
Age at Study Initiation:	Ca. 5 months old	Birds were younger than recommended (≥30 weeks). It was stated that birds were approaching their first breeding season.
	1.9	Birds approaching their first breeding season should be used.
Body Weight: (mean and range)	Males: Overall range (n=80) of 175.1 to 243.8 g, with group means of 207.1 to 209.5 g.	Body weights were recorded at weeks 0, 2, 4, 6, 8, and 22 (adult termination).
	Females: Overall range (n=80) of 172.2-249.8 g, with group means of 202.0 to 204.4 g.	Body weights should be recorded at test initiation and at biweekly intervals up to week eight or up to the onset of egg laying and at termination.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks
		Criteria
Source:	H. & E. Küberich, Wiesentheid/Geesdorf, Germany	All birds should be from the same source.

B. STUDY DESIGN:

1. Experimental Conditions

a. Range-finding study: None reported.

b. Definitive Study

Table 2: Experimental Parameters.

Parameter	Details	Remarks	
		Criteria	
Acclimation period: Conditions (same as test or not):	3 weeks Same as test	During acclimation, birds were inspected daily for health and received 7 hours of light/day.	
Feeding: Health (any mortality observed):	"Provimi Kliba SA" commercial diet for quails and ducks in meal form (Kaiseraugst, Basel, Switzerland) and municipal water from the city of Frankenthal were offered <i>ad libitum</i> 1.6% mortality during acclimation; all deaths were the result of injuries from fighting.	Recommended observation period includes a 2-3 week health observation period prior to selection of birds for treatment. Generally, birds should be healthy without excess mortality. Feeding should be ad libitum, and sickness, injuries or mortality should be noted.	
Test duration			

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks
		Criteria
pre-laying exposure: egg-laying exposure: withdrawal period, if used:	10 weeks 12 weeks N/A	Recommended pre-laying exposure duration: At least 10 weeks prior to the onset of egg-laying. Recommended exposure duration with egg-laying: At least 10 weeks. Recommended withdrawal period: If reduced reproduction is evident, a withdrawal period of up to 3 weeks should be added to the test phase.

EPA MRID Number: 47699904

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030

Parameter	Details	Remarks <i>Criteria</i>
Pen (for parental and offspring) size:	Parents (one pair) were housed in battery cages measuring 0.59 x 0.45 x 0.26 m. Offspring (by set and group) were housed in open-topped pens measuring 0.65 x 1.3 m during egg-laying week 1 or 0.65 x 2.6 m during egg-laying weeks 2-12.	Cage size was significantly smaller than recommended. OPPTS recommends at least 5,000 cm ² per bird. In this study, the floor space was only 1,328 cm ² per bird. Cage sizes smaller than recommended should be shown to not adversely affect the health or reproduction of the quail.
construction materials:	Parental pens were constructed of stainless steel wire-mesh, with sloping wire mesh floors and egg catchers. Offspring pens were constructed of plastic; the floor inside the pens was covered with corrugated board. 16 parental pens/treatment level. Hatchlings were group-housed according to the appropriate parental concentration.	Pens Pens should have adequate room and be arranged to prevent cross-contamination. Materials Recommended materials include nontoxic material and nonbinding material, such as galvanized steel. Number At least 5 replicate pens should be used for mallards housed in groups of 7. For other arrangements, at least 12 pens should be used, but considerably more may be used if birds are kept in pairs. Chicks should be housed according to parental grouping.
Number of birds per pen (male:female)	2 birds/pen (1 male:1 female)	One male and one female per pen should be used. For quail, one male and two females should be used. For ducks, two males and five females should be used.
Number of pens per group/treatment negative control: solvent control: treated:	16 pens N/A 16 pens/treatment	During the pre-egg-laying period, four additional replicates with spare birds were maintained for each of the four test groups under the same conditions.
		At least 12-16 pens should be used, but considerably more if birds are kept in pairs.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks	
		Criteria	
Test concentrations (mg a.i./kg diet) nominal:	0 (control), 100, 300, and 1000 mg a.i./kg diet	Nominal concentrations were adjusted for the purity of the test substance.	
measured:	<10.0 (<loq, 96.0,<br="" control),="">282, and 940 mg a.i./kg diet, respectively (equivalent to 7.3, 20.7, and 70.1 mg a.i./kg bw, respectively)</loq,>	Measured concentrations were determined at all levels during Weeks -1 (fresh diet mixes), 2 (from feed hoppers), 10 (from storage containers), and 20 (from storage containers). Measured concentrations ranged from 91-102% of nominal concentrations, and averaged 94-96% for all treatment levels.	
		Recommended test concentrations include at least two concentrations other than the control, three or more will provide a better statistical analysis. The highest test concentrations should show a significant effect or be at or above the actual or expected field residue level.	
Maximum labeled field residue anticipated and source of information:	Not specified	It was reported that the U.S. EPA recommends an upper limit concentration of 1000 mg/kg diet for avian reproduction studies.	
		The highest test concentrations should show a significant effect or be at or above the actual or expected field residue level. The source (i.e., maximum label rate in lb ai/A and ppm), label registration no., label date, and site should be cited]	
Solvent/vehicle, if used type: amount:	N/A	Recommended solvents include corn oil or other appropriate vehicle not more than 2% of diet by weight	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks	
		Criteria	
Was detailed description and nutrient analysis of the basal diet provided? (Yes/No)	Yes. The basal ration (three batches) contained 23.3-24.9%	Offspring were fed basal ration without the addition of test substance.	
	crude protein, 6.8-7.3% crude fat, and 2.7-3.5% crude fiber.	A commercial breeder feed or an equivalent that is appropriate for the test species is recommended.	
Preparation of test diet	Three days prior to study initiation, the appropriate amount of test substance was mixed with diet in a beaker. Thereafter, each premix was adjusted to the desired concentration with the appropriate amount of feed and mixed for about 10 minutes in a laboratory mixer. Treated feed was prepared every week during the study, and was stored at ambient temperature.	A premixed diet containing the test substance should be mechanically mixed with basal diet. If an evaporative vehicle is used, it should be completely evaporated prior to feeding.	
Indicate whether stability and homogeneity of test material in diet determined (Yes/No)	Yes		
Were concentrations in diet verified by chemical analysis?	Yes		

EPA MRID Number: 47699904

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030

Parameter	Details	Remarks	
	Details	Criteria	
Did chemical analysis confirm that diet was stable?	Yes.	Stability was assessed in treated feed prepared at all treatment levels after 10 days of ambient storage (including 7 days in open feeders) during Week 1 (batch test diets were prepared 3 days prior to test initiation). Recoveries averaged 90.1-99.4%	
		of nominal concentrations.	
and homogeneous?	Yes	Homogeneity was assessed in freshly-prepared treated feed at the 100 and 1000 mg/kg diet levels on Day -3. One sample	
		was collected from the upper, middle, and lower layer of each level. Reviewer-calculated coefficients of variation (CV=RSD) were 0.4 and 0.14%, respectively.	
Feeding and husbandry	Feeding and husbandry conditions appeared to be adequate, given guideline recommendations.		
Test conditions (pre-laying) temperature: relative humidity: photoperiod:	20.8 ± 0.6°C (19.0-26.9°C) 52 ± 8% (25-100%) 7 hr light/day up through Week 7; 14 hr light/day during Weeks 8 and 9; and 17 hr light/day thereafter.	Temperature and humidity were for the adult room during the entire study. The air handling system provided <i>ca.</i> 15 room air volumes every hour. Light intensity was approximately 25-168 Lux.	
		Recommended temperature: about 21EC (70EF) Recommended relative humidity: about 55% Recommended lighting First 8 weeks: 7 h per day. Thereafter: 16-17 h per day. At least 6 foot-candles are recommended at bird level.	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks
		Criteria
Egg Collection and Incubation		
Egg collection and storage collection interval: storage temperature: storage humidity:	Daily Ca. 16 ± 1°C Ca. 60-86%	Eggs should be collected daily; recommended egg storage temperature is approximately 16°C (61°F); recommended humidity is approximately 65%. Recommended collection interval: daily
Were eggs candled for cracks prior to setting for incubation?	Yes	Eggs should be candled on day 0
Were eggs set weekly?	Yes	
When candling was done for fertility?	Eggs were candled again on Days 11 (embryo viability) and 18 (embryo survival).	Quail: approx. day 11 Ducks: approx. day 14
When the eggs were transferred to the hatcher?	Day 21	Bobwhite: usually day 21 Mallard: usually day 23
Hatching conditions temperature:	Ca. 37.7-37.9°C Ca. 80-90%	An area with a higher temperature $(40 \pm 2^{\circ}\text{C})$ was maintained by ceramic radiant heaters above the hatchling cages.
photoperiod:	17 hr light/day (hatchlings)	Recommended temperature is 39°C (102°F) Recommended humidity is 70%
Day the hatched eggs were removed and counted	Day 25, within approximately 24 hours of hatching	Eggs for bobwhite should be removed on day 24; for mallard on day 27
Were egg shells washed and dried for at least 48 hrs before measuring?	Yes	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks
		Criteria
Egg shell thickness no. of eggs used:	One egg of each pair that laid at least one egg.	Newly hatched eggs should be collected at least once every two
intervals:	Weeks 1, 3, 5, 7, 9, and 11 of the egg production period.	weeks. Thickness of the shell plus membrane should be measured to the nearest 0.01 mm with 3 - 4 measurements per shell.
mode of measurement:	Four points around the girth of the shell using a micrometer graduated to 0.01 mm.	
Reference chemical, if used	None used	

2. Observations:

Table 3: Observations.

Parameter	Details	Remarks
Parameters measured		
Parental (mortality, body weight, mean feed consumption)	- mortality - body weight - food consumption - signs of toxicity	Extra birds which were sacrificed at the end of the pre-egg laying period and those which were terminated because the pen-mate had died were not examined post-mortem.
Egg collection and subsequent development (no. of eggs laid, no. of eggs cracked, shell thickness, no. of eggs set, no. of viable embryos, no. of live 3 week embryos, no. hatched, no. of 14-day survivors, average weight of 14-d old survivors, mortality, gross pathology, others)	- palatability - necropsy - eggs laid - eggs cracked - egg weight - egg shell thickness - eggs set - viable embryos - live 3-week embryos - chicks dead in shell - number of hatchlings - hatchling abnormalities - hatchling body weight - number of 14-day-old survivors - 14-day-old survivor body weight - signs of toxicity of hatchlings	Recommended endpoints measured include: Eggs laid/pen Eggs cracked/pen Eggs set/pen Viable embryos/pen Live 3-week embryos/pen Normal hatchlings/pen 14-day-old survivors/pen Weights of 14-day-old survivors (mean per pen) Egg shell thickness Food consumption (mean per pen) Initial and final body weight (mean per pen)

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Details	Remarks
Indicate if the test material was regurgitated	No indications of dietary regurgitation.	
Observation intervals (for various parameters)	Parental and hatchling mortality and signs of toxicity were recorded once daily. Parental body weights were recorded at weeks 0, 2, 4, 6, 8, and 22 (adult termination). Parental food consumption was measured weekly throughout the test.	Body weights and food consumption should be measured at least biweekly
Were raw data included?	Yes	

II. RESULTS AND DISCUSSION:

A. MORTALITY:

There was no mortality that could be attributed to the test substance. Ten incidental mortalities occurred during the study: two in the control group, three in the 300 mg a.i./kg diet group, and five in the 1000 mg a.i./kg diet group.

One control female was sacrificed *in extremis* during Week 5 due to lesions on both feet. Another control female was found dead during Week 14; no signs of illness or gross post-mortem abnormalities were observed, and the cause of death was unknown.

At the 300 mg a.i./kg diet level, two females were found dead, one during Week 9 and another during Week 17; the causes of death were unknown. Necropsy of the female found dead during Week 17 revealed lesions on both feet with the surface partly encrusted; no other abnormalities were detected at necropsy and no signs of illness were observed prior to death of either bird. Another female from this level was sacrificed *in extremis* during Week 12 due to head injuries from fighting; aside from head lesions with partial ulceration, no other abnormalities were observed at necropsy.

At the 1000 mg a.i./kg diet level, one male was found dead during Week 10, and another two females were found dead, one each during Weeks 13 and 22; no signs of illness or gross post-mortem abnormalities were observed, and the causes of death were unknown. Two additional females from this level were sacrificed *in extremis*: one during Week 12 due to head injuries from fighting and another during Week 20 due to foot lesions. Aside from the associated lesions due to the injuries, no further abnormalities were observed upon necropsy of these birds.

No other mortalities were observed during the study, and based upon the findings at necropsy, all deaths were considered incidental to treatment. The NOAEC for adult mortality was 1000 mg a.i./kg diet.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Table 4: Effect of BAS 800 H (Saflufenacil) on Mortality of Northern Bobwhite.

Treatment	Observation Period									
(mg a.i./kg diet) Mean-measured (and Nominal)	W	eek 7	w	eek 15	w	Week 22				
Concentrations	No. Dead Male Female		Male No	. Dead Female	No. Dead Male Female					
Control	0	1	0	2	0	2				
96.0 (100)	0	0	0	0	0	0				
282 (300)	0	0	0	2	0	3				
940 (1000)	0	0	1	2	1	4				

B. REPRODUCTIVE AND OTHER ENDPOINTS:

Abnormal Effects/Behavior: No overt signs of toxicity were observed in any treatment group. Incidental clinical observations included moderate lesions from fighting and subsequent injuries. In addition, transient diarrhea was observed for 9 days in one cage at the 1000 mg a.i./kg diet level. The NOAEC for clinical signs of toxicity was 1000 mg a.i./kg diet.

Food Consumption: No rejection of food containing the test substance was observed, and no apparent treatment-related effects on feed consumption were evident at any concentration level tested. Statistical evaluation revealed a statistically-significant increase at the 1000 mg a.i./kg diet level compared to the control during Weeks 8 (14.3 versus 13.0 g/bird/day; p \leq 0.01), 16 (23.8 versus 20.5 g/bird/day; p \leq 0.05), and 20 (17.7 versus 13.3 g/bird/day; p \leq 0.05), and a significant decrease at the 1000 mg a.i./kg diet level compared to the control during Week 17 (13.1 versus 17.1 g/bird/day; p \leq 0.05). Since the mean values for all groups were within a narrow range and no dose-related trend was observed, the differences observed were considered incidental to treatment by the study authors. The NOAEC for feed consumption was 1000 mg a.i./kg diet.

Overall mean feed consumption was 15.9, 16.4, 16.2, and 16.1 g/bird/day for the 0, 100, 300, and 1000 mg a.i./kg diet groups, respectively. The calculated mean uptake of test substance was 1.58, 4.55, and 15.15 mg a.i./bird/day for the 100, 300, and 1000 mg a.i./kg diet groups, respectively. The calculated daily dose was 7.3, 20.7, and 70.1 mg a.i./kg bw, respectively.

<u>Body Weight</u>: A statistically significant decrease in hatchling body weight was observed at the 1000 mg a.i/kg diet dose in week 1-4, 9-12, and over the total egg-laying period. Although the trend was clearly dose-related and could be seen over the whole egg-laying period, the study authors report the finding as a "borderline effect of the test substance, but not biologically adverse effect". The study authors conclude that the test substance did cause a slight but not biologically adverse effect on chick body weight at hatch.

<u>Necropsy</u>: There were no macroscopic findings upon necropsy of surviving birds that were considered related to treatment.

Egg production and quality: No statistically-significant differences in overall egg production, overall egg weight, or mean egg shell thicknesses were observed at any treatment level compared to the control. A small, statistically-

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

significant increase in the percentage of cracked and broken eggs of eggs laid was observed at the 100 mg a.i./kg diet level compared to the control (9.7 versus 6.1%; $p \le 0.05$); however, no dose-related trend was observed, and the difference was not considered to be related to treatment by the study authors.

Embryo survival: The number of fertile eggs totaled 714, 708, 669, and 551 for the control, 100, 300, and 1000 mg a.i./kg diet groups, respectively, and the corresponding overall fertility rates were 94.7, 86.7, 93.3, and 81.9%, respectively. A slight, statistically-significant reduction in the proportion of fertile eggs of eggs set was observed at the 1000 mg a.i./kg diet level compared to the control (p≤0.05). The study author reported that the fertility rate of the 1000-mg a.i./kg group was within the normal values for the control group given in the test guidelines, while the fertility rate of the control observed in this study was above the range of the historical controls (79.1-98.6% in the last 18 studies carried out in the laboratory since 1993). Furthermore, it was reported that the statistically-significant difference observed was mainly a consequence of the markedly decreased number of fertile eggs on the onset of the egg-laying period. Thus, the decreased fertility rate at the highest treatment level was not considered to be an effect of the test substance.

For the control, 100, 300, and 1000 mg a.i./kg diet levels, the rates of viable 11-day embryos of eggs initially set were 92.7, 84.4, 92.1, and 79.0%, respectively, the rates of live 18-day embryos of viable 11-day embryos were 99.5, 99.0, 99.6, and 98.8%, respectively, and the rates of "dead-in-shell" of fertile eggs were 14.6, 15.0, 11.4, and 14.6%, respectively. No statistically-significant differences from the control were observed for any endpoint.

Hatching and hatchlings: The proportion of hatched chicks of live 18-day embryos was 82.7, 81.1, 86.8, and 80.0% for the control, 100, 300, and 1000 mg a.i./kg diet levels, respectively, with no statistically-significant differences from the control observed. No clinical signs of toxicity were observed at any treatment level. Although a small percentage of chick hatched had crippled feet or a malformed spinal column, these effects were seen in all test groups including the control and were clearly not related to treatment.

For all test groups including the control, the survival after hatch decreased during the last 5 weeks of the egg-laying period. Therefore, the length of the egg-laying period resulted in a relatively low survival rate of chicks after hatch. The proportion of 14-day survivors to number of hatchlings were 66.9, 76.7, 67.4, and 55.9% for the control, 100, 300, and 1000 mg a.i./kg diet levels, respectively. No statistically-significant differences to the control were observed over the whole egg-laying period for any level. In addition, there were no statistically-significant differences compared to the control in the mean numbers of 14-day surviving chicks per female and week.

Although no statistically-significant differences compared to the controls were observed by the study author in the 14-day survivors' body weights over the whole egg-laying period, a statistically-significant decrease in mean hatchlings' body weight was observed at the 1000 mg a.i/kg diet dose. However, the study authors report the finding as a "borderline effect of the test substance, but not biologically adverse effect".

Overall, there were no biologically-significant treatment-related effects on the reproductive parameters in any treatment level; the NOAEC for all applicable endpoints was 1000 mg a.i./kg.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Table 5: Reproductive and Other Parameters (nominal concentrations; study author-reported).

Parameter	Control	100 mg a.i./kg	300 mg a.i./kg	1000 mg a.i./kg	NOAEC/ LOAEC
Eggs laid	873	988	815	743	N/A
Eggs laid/hen/week	4.5	5.1	4.2	3.9	1000 mg a.i./kg >1000 mg a.i./kg
Eggs cracked	46	88	32	51	N/A
Egg weight (g)	10.4	10.2	10.1	9.8	1000 mg a.i./kg >1000 mg a.i./kg
Eggs set	754	819	717	625	N/A
Shell thickness (mm)	0.20	0.19	0.20	0.19	1000 mg a.i./kg >1000 mg a.i./kg
Viable embryos	700	687	659	538	N/A
Live 3-week embryos	697	682	656	535	N/A
No. of hatchlings/hen/week	3.1	3.0	3.0	2.4	1000 mg a.i./kg >1000 mg a.i./kg
No. of hatchlings	597	575	571	454	N/A
Hatchling weight (g)	6.5	6.4	6.2	5.9*	1000 mg a.i./kg >1000 mg a.i./kg
14-day old survivors	414	442	367	296	N/A
14-day old survivors/hen/week	2.2	2.3	1.9	1.6	1000 mg a.i./kg >1000 mg a.i./kg
14-day old survivors weight (g)	21.3	20.9	20.6	20.5	1000 mg a.i./kg >1000 mg a.i./kg
Mean food consumption (g/bird/day)	15.9	16.4	16.2	16.1	1000 mg a.i./kg >1000 mg a.i./kg
Weight (g) of parent females at test initiation:	204.3	202.0	203.3	204.4	1000 mg a.i./kg

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Parameter	Control	100 mg a.i./kg	300 mg a.i./kg	1000 mg a.i./kg	NOAEC/ LOAEC
at onset of egg laying:	204.5	209.5	207.7	209.0	>1000 mg
at test termination:	239.2	241.7	244.9	232.2	a.i./kg
Weight (g) of parent males at test initiation: at onset of egg laying: at test termination:	209.5	207.1	208.8	207.9	1000 mg a.i./kg
	212.9	214.5	213.4	209.0	>1000 mg
	214.2	212.3	220.1	219.4	a.i./kg
Gross pathology	No treatmen	t-related abnorm	nalities observed.		

N/A = Not statistically-analyzed.

C. REPORTED STATISTICS:

The following variables were statistically analyzed: adult body weight, adult feed consumption, eggs laid per female, proportion of eggs damaged of egg laid, egg weight, egg shell thickness, proportion of fertile eggs of eggs initially set, proportion of viable 11-day embryos of eggs initially set per female, proportion of early embryonic deaths on day 11 of fertile eggs per female, proportion of late embryonic deaths on day 18 of fertile eggs per female, proportion of viable 18-day embryos of eggs initially set per female, proportion of viable 18-day embryos of fertile eggs per female, proportion of viable 11-day embryos per female, proportion of "dead-in-shell" of fertile eggs per female, hatched chicks per female, proportion of normal hatchlings of eggs set per female, proportion of normal hatchlings of fertile eggs per female, proportion of 14-day old survivors per female, proportion of 14-day old survivors of eggs set, proportion of 14-day old survivors of fertile eggs per female, proportion of 14-day old survivors of normal hatchlings per female, means for hatched chicks' body weight at day 0, and means for 14-day surviving chicks' body weight.

For the body weight and food consumption of parent birds, for the egg weight, egg shell thickness, and chicks' body weight, a comparison of each dose group with the control group was performed using a two-sided Dunnett's test for the hypothesis of equal means. For count data (e.g., no of eggs, no. of hatched chicks) and proportions (e.g., no. of fertile eggs of initially set), a nonparametric analysis was carried out. A pairwise comparison of each dose group with the control was performed via the one-sided Wilcoxon test for the hypothesis of equal medians.

Sample units were the individual pens within each experimental group, except adult body weights, where the sample unit was the individual bird. If proportions were analyzed, sums of each pen were used in the numerator and in the denominator. The statistical analyses were performed using the SAS-System. For the analysis of the body weight and of the food consumption of parent birds, the DATATOX F1-System was used. Nominal concentrations were used for all estimations.

D. VERIFICATION OF STATISTICAL RESULTS:

Statistical Method: Analysis was conducted using "chicks.sas" (Ver. 3; March 2002), a SAS program provided by EFED/OPP/USEPA. Data for all endpoints were examined graphically using box plots to determine if they

^{*} Statistically significantly different to the control group (p < 0.01).

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

exhibited a dose-dependent response, which was ultimately used to select the multiple comparison test to detect LOAEC and NOAEC. Data for each endpoint were tested to determine if their distributions were normal and if their variances were homogeneous using Shapiro-Wilk's and Levene's tests, respectively. Data that satisfied these assumptions were subjected to Dunnett's and William's tests and data that did not satisfy these assumptions were subjected to the non-parametric MannWhitney-U (with a Bonferroni adjustment) and Jonckheere's tests. Data for dead birds were excluded from the analyses. See Appendix I for output of reviewer's statistical verification and graphs for affected endpoints to support any reviewer-generated conclusions that may differ from those reported in the study.

NOAEC: 96.0 mg a.i./kg diet LOAEC: 282 mg a.i./kg diet

Endpoint(s) Affected: hatchling body weight

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Table 6: Reproductive and Other Parameters (mean-measured concentrations; reviewer-reported).

Parameter	Control	96.0 mg a.i./kg	282 mg a.i./kg	940 mg a.i./kg	NOAEC/ LOAEC
Eggs laid/pen	58.2	61.8	54.3	53.1	940 mg a.i./kg >940 mg a.i./kg
Eggs cracked/pen	3.1	5.5**	2.1	3.6	940 mg a.i./kg >940 mg a.i./kg
Eggs not cracked/eggs laid (%)	93.9	90.3	90.1	93.8	940 mg a.i./kg >940 mg a.i./kg
Eggs set/pen	50.3	51.2	47.8	44.6	940 mg a.i./kg >940 mg a.i./kg
Shell thickness	0.20	0.20	0.20	0.20	940 mg a.i./kg >940 mg a.i./kg
Eggs set/eggs laid (%)	85.3	82.0	81.3	81.8	940 mg a.i./kg >940 mg a.i./kg
Viable embryos/pen	47.6	44.2	44.6	39.4	940 mg a.i./kg >940 mg a.i./kg
Viable embryos/eggs set (%)	94.7	86.7	93.3	82.0	940 mg a.i./kg >940 mg a.i./kg
Live embryos/pen	46.5	42.6	43.7	38.2	940 mg a.i./kg >940 mg a.i./kg
Live embryos/viable embryos (%)	97.2	96.0	98.2	94.6	940 mg a.i./kg >940 mg a.i./kg
No. of hatchlings/pen	39.8	35.9	38.1	32.4	940 mg a.i./kg >940 mg a.i./kg
No. of hatchlings/eggs laid (%)	67.1	58.0	65.6	55.3	940 mg a.i./kg >940 mg a.i./kg
No. of hatchlings/eggs set (%)	78.4	70.9	80.9	65.8	940 mg a.i./kg >940 mg a.i./kg
No. of hatchlings/live embryos (%)	85.0	84.0	88.4	83.8	940 mg a.i./kg >940 mg a.i./kg
Hatchling survival/pen	27.6	27.6	24.5	21.1	940 mg a.i./kg >940 mg a.i./kg
Hatchling survival/eggs set (%)	52.7	54.0	55.0	40.7	940 mg a.i./kg >940 mg a.i./kg

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Hatchling survival/no. of hatchlings (%)	66.9	76.7	67.4	59.9	940 mg a.i./kg >940 mg a.i./kg
Hatchling weight (g)	6.58	6.44	6.25*	5.98***	96.0 mg a.i./kg 282 mg a.i./kg
Survivor weight (g)	21.4	20.8	19.2	20.4	940 mg a.i./kg >940 mg a.i./kg
Mean food consumption (g/bird/day)	15.9	16.5	16.1	16.2	940 mg a.i./kg >940 mg a.i./kg
Male weight gain (g)	5.8	6.8	10.9	5.5	940 mg a.i./kg >940 mg a.i./kg
Female weight gain (g)	31.9	39.9	38.0	25.5	940 mg a.i./kg >940 mg a.i./kg

^{*} Statistically different from the control at p<0.05.

E. STUDY DEFICIENCIES:

There were no study deficiencies.

F. REVIEWER'S COMMENTS:

Results of the reviewer's statistical verification differed from the study author's for the hatchling body weight parameter. The study authors observed a statistically-significant difference in hatchling body weight at the highest dose, but discounted the effect as "slight" and not biologically adverse. The reviewer disagrees with the study author's interpretation of the hatchling body weight results. The reviewer's analysis detected significant reductions in hatchling body weight at the two highest treatment levels; 5.4% (p=0.031) and 9.5% (p<0.001) reductions in hatchling body weight were observed at the 282 and 940 mg a.i./kg levels, respectively. It is U.S. EPA's policy to base endpoint selection on the most sensitive treatment-related parameter related to survival, growth, or fecundity that is statistically and/or biologically significant as compared to the control. In addition, a clear dose-related effect was observed for the hatchling body weight parameter. The reviewer calculated mean hatchling body weight by summing the weekly day 0 chick body weights for each replicate and dividing this sum by the total number of hatched chicks per replicate. The spreadsheet used to perform these calculations is provided with the raw data files submitted with this DER. With the exception of the hatchling body weight analysis, the reviewer's calculations agreed with the study author's for all other levels and endpoints. The reviewer's conclusions, based on meanmeasured concentrations and daily doses, are reported in the Executive Summary and Conclusions sections of the DER.

All validity requirements were met. Specifically, controls produced an average of 26 14-day old survivors per hen during the 12-week production phase (minimum of 12 quail per pen during a 10-week production phase), the egg shell thickness of control eggs was 0.20 mm (minimum of 0.19 mm for quail), and 6% adult control mortality was observed during the study (no more than 10% acceptable in controls).

^{**} Statistically different from the control at p<0.01.

^{***} Statistically different from the control at p<0.001.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

During the egg-laying period, severe injuries from fighting were observed in some of the pairs. For humane reasons, the pairs were separated for 1 to 2 weeks, which was needed to cure the injuries. After the condition of the injured bird was improved, the pairs were reunited. Affected pairs included: Pair 19 of the control group for egg-laying weeks 3 to 5; Pair 24 of the 100-mg/kg group for egg-laying weeks 4 to 5, and Pair 32 for weeks 5 to 6; Pair 42 of the 300-mg/kg group for egg-laying weeks 4 to 6, and Pair 52 for weeks 4 to 5; and Pairs 61 and 69 of the 1000-mg/kg group for egg-laying weeks 4 to 5. It was reported that since eggs were laid also during the separation period and in the week after, the separation time was too short to influence the fertilization time markedly. Thus, egg data obtained during separation was not excluded from the statistical evaluation.

Ten-gram portions of treated-diet samples were combined with 20 mL of double-distilled water and allowed to sit for 20 minutes at ambient temperature. The samples were then extracted twice with 35 mL of acetonitrile by shaking 30 minutes at ambient temperature and subsequent sonification (5 minutes). The extracts were combined, filtered, and diluted with acetonitrile (to 100 mL) prior to analysis by HPLC with UV (270 nm) detection. The analytical LOQ was 1.00 mg/L, corresponding to 10.0 mg/kg feed.

In method validation assessments, the average recoveries of the test substance were $100.1 \pm 1.9\%$ and $84.7 \pm 4.6\%$ in fortified feed samples containing 500 and 5000 mg/kg BAS 800 H, respectively.

In-life dates were February 16 – August 28, 2006.

G. CONCLUSIONS:

This study is scientifically sound and is classified as ACCEPTABLE to U.S. EPA and as FULLY RELIABLE to PMRA and APVMA. The reviewer's analysis detected significant reductions in hatchling body weight at the two highest treatment levels. No other biologically-significant treatment-related effects were observed on any adult or offspring parameter.

NOAEC: 96.0 mg a.i./kg diet (7.3 mg a.i./kg bw) LOAEC: 282 mg a.i./kg diet (20.7 mg a.i./kg bw) Endpoint(s) Affected: hatchling body weight

III. REFERENCES:

A reference list was not provided.

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Boby	white	qua	il ı	repro, Sa	aflui	Fenacil	, MRI	D 471279-1	.5				
PRI	TUOTE	OF	RAW	DATA									
Obs	TRT	EL.	EC	ENC_EL	ES	ES_EL	VE	VE_ES	$_{ m LE}$	LE_VE	NH	NH_EL	NH_ES
1	Ctrl	77	3	96.10	68	88.31	65	95.59	62	95.38	51	66.23	75.00
2	Ctrl	67	2	97.01	60	89.55	45	75.00	43	95.56	40	59.70	66.67
3	Ctrl	65	5.	92.31	55	84.62	48	87.27	48	100.00	37	56.92	67.27
4	Ctrl	64	3	95.31	55	85.94	54	98.18	54	100.00	38	59.38	69.09
5	Ctrl	72	1	98.61	65	90.28	64	98.46	64	100.00	53	73.61	81.54
6	Ctrl	68	1	98.53	61	89.71	60	98.36	60	100.00	58	85.29	95.08
7	Ctrl			•		•		•					•
8	Ctrl	77	2	97.40	69	89.61	67	97.10	66	98.51	60	77.92	86.96
9	Ctrl	31	1	96.77	27	87.10	27	100.00	27	100.00	20	64.52	74.07
10	Ctrl					•				-		•	
11	Ctrl	68	4	94.12	59	86.76	59	100.00	5.7	96.61	54	79.41	91.53
12	Ctrl	52	2	96.15	46	88.46	44	95.65	44	100.00	41	78.85	89.13
13	Ctrl	62	4	93.55	53	85.48	53	100.00	53	100.00	49	79.03	92.45
14	Ctrl	25	5	80.00	17	68.00	17	100.00	17	100.00	15	60.00	88.24
15	Ctrl					•	٠.						
16	Ctrl	64	3	95.31	56	87.50	56	100.00	53	94.64	42	65.63	75.00
17	Ctrl	47	9	80.85	33	70.21	26	78.79	22	84.62	17	36.17	51.52
18	Ctrl											•	
19	Ctrl	34		97.06	30	88.24	29	96.67	27	93.10	21	61.76	70.00
20	Ctrl			_									
21	Dose1			95.31	56	87.50	56	100.00	54	96.43	50	78.13	89.29
22	Dose1							-					•
23	Dose1			85.45	42	76.36	42	100.00	41	97.62	35	63.64	83.33
24	Dose1			73.91	30	65.22	29	96.67	28	96.55	22	47.83	73.33
25	Dose1			92.50	68	85.00		95.59	65	100.00	56	70.00	82.35
26	Dose1												
27	Dose1			95.65	61	88.41	58	95.08	58	100.00	49	71.01	80.33
28	Dose1			90.00	49	81.67	3.1	63.27	31	100.00	27	45.00	55.10
29	Dose1			76.92	26	66.67	23	88.46	23	100.00	20	51.28	76.92
30	Dose1			91.55	60	84.51	33	55.00	32	96.97	28	39.44	46.67
31	Dose1			88.89	50	79.37	50	100.00	49	98.00	43	68.25	86.00
32	Dose1			93.33	51	85.00	24	47.06	21	87.50	15	25.00	29.41
33	Dose1			94.59	64	86.49	49	76.56	37	75.51	23	31.08	35.94
34	Dose1				46	88.46		76.09	34	97.14	32	61.54	69.57
35	Dose1			86.21	46	79.31		97.83	41	91.11	35	60.34	76.09
36	Dose1			97.33	67	89.33	67	100.00	67	100.00	48	64.00	71.64
37	Dose1			90.91	45	81.82	44	97.78	44	100.00	41	74.55	91.11
38	Dose1			J0.J1		01.02		37.70					
39	Dose1		•	•		•	•	•					•
40	Dose1					86.57			57	100.00			87.93
41	Dose2												
42	Dose2				•	•		•	:			•	•
43	Dose2							72.58	41	91.11	35	50.72	56.45
44 .	Dose2									98.15	49	75.38	89.09
45	Dose2				43			97.67	42	100.00	40	80.00	93.02
46	Dose2				56			100.00	56	100.00	42	64.62	75.00
47	Dose2				3			100.00	3	100.00	3	75.00	100.00
48	Dose2				57			98.25	55	98.21	45	68.18	78.95
48	Dose2			100.00	33			100.00	32	96.97	26	72.22	78.79
せフ	שטטטע		. 0	100.00	23	21.07	22	100.00	22	50.57	20	,	, , , ,

			Tumber: 20	08-043	30					T717.4 *	TO TO	NT1.	17/00004	
PMI	KA Doci	iment ID	: 1731030							EPA I	<u>ARID</u>	Number: 4	17699904	
50	Dose2	68 3	95.59	60	88.24	58	96.6	7	56	96.55	49	72.06	81.67	
51	Dose2		98.59	64	90.14	63	98.4		62	98.41	51	71.83	79.69	
52	Dose2		95.74	40	85.11	23	57.5		23	100.00	22	46.81	55.00	
53	Dose2		94.64	48	85.71	46	95.8		46	100.00	45	80.36	93.75	٠,
54	Dose2		95.83	64	88.89	64	100.0		63	98.44	54	75.00	84.38	
55	Dose2										•			
56	Dose2		98.53	62	91.18	62	100.0	0	61	98.39	50	73.53	80.65	٠
57	Dose2													
58	Dose2	1 1	0.00	0	0.00	0			0		0	0.00		
59	Dose2		98.70	70	90.91	64	91.4	3	63	98.44	60	77.92	85.71	
60	Dose2									• .				
61	Dose3	7 0	100.00	4	57.14	0	0.0	0	0		0	0.00	0.00	
62	Dose3		98.11	47	88.68	33	70.2		33	100.00	31	58.49	65.96	•
63	Dose3		100.00	10	76.92	. 9	90.0		7	77.78	5	38.46	50.00	
64	Dose3										, ,			
65	Dose3		96.77	55	88.71	51	92.7	13	50	98.04	39	62.90	70.91	
66	Dose3												, 0.31	
67	Dose3				•					·	•			
68	Dose3		95.45	58	87.88	52	89.6	6	51	98.08	47	71.21	81.03	
69	Dose3		90.14	58	81.69	35	60.3		34	97.14	32	45.07	55.17	
70	Dose3		97.14	31	88.57	29	93.5		29	100.00	25	71.43	80.65	
71	Dose3		84.44	34	75.56	34	100.0		34	100.00	31	68.89	91.18	
72	Dose3		91.67	60	83.33	59	98.3		59	100.00	50	69.44	83133	
73	Dose3		87.27	43	78.18	38	88.3		38	100.00	31	56.36	72.09	
74	Dose3		94.81	67	87.01	67	100.0		66	98.51	49	63.64	73.13	
75	Dose3		91.78	61	83.56	58	95.0		58	100.00		75.34	90.16	
76	Dose3	75 0	71.70	•					50	100.00	55	/3.54	50.10	٠
77	Dose3	•	•	•	•	•		`	•	•	•	. •	•	
78	Dose3	 44 5	88.64	34	77.27	24	70.5	: a	15	62.50	10	22.73	29.41	
79	Dose3		97.14	63	90.00	62	98.4		÷3	98.39		70.00	77.78	
80	Dose3	, o 2	77.11	05	20.00	02	70.5		0 ±	20.32	4,7	,0.00	,,.,	
		· . r lieum	repro, Sa	• • f l : : f :	· anacil	MD:	TD 47127	70_1	5	•	•	•		
			DATA (co			I-IIC.	ID 4/12/	, ,	5					
	TRT	NH_LE		IS_ES		יי א	HICK HAT	ידיזעוי	GITE	VWT F	OOD	WITCIATNM	WTGAINF	
1	Ctrl	82.26		53.24			0.20	7		22	16	10	21	
2	Ctrl	93.02		36.67			0.21	6		18	17	3	43	
3	Ctrl	77.08		13.64			0.20	6		20	16	-50	26	
4	Ctrl				84.2					21	16	- 50	33	
5			34 5								16	_	37	
6			7 43					6			17	18	52	
7		30.0			,									
8	Ctrl	90.91		59.42			0.19	7		23	15	-13	35	
9	Ctrl	74.07									15	-±3 5		
10	Ctrl	,4.0		18.52			0.20	6		21			. 16	
11	Ctrl			54.41			0.20	7		· 24	17	32	47	
	Ctrl	94.74		59.57			0.20	· 7		24	17			
13	Ctrl	93.18										-17 13		
				59.81			0.18	6					15	
•	Ctrl			52.94			0.20	7		20	15	36		
	Ctrl	70.05		. 70	60.0		• .	• ·		22	• ·	•	2.0	
	Ctrl Ctrl			51.79			0.19	7		22 25	15	7	30	
1/	CCTT	11.2	7 15 4	15.45	88.2	'±	0.20	7		45	15	26	44	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030								EPA MRID Number: 47699904				
19	Ctrl	77.78	10	33.33	47.62	0.20	7	21	17	-16	29 .	
20	Ctrl		•						± ′			
21	Dose1	92.59	32	57.14	64.00	0.19	6	21	17	11	13	
22	Dose1		•							•		
23	Dose1	85.37	20	47.62	57.14	0.19	7	24	17	5	44	
24	Dose1	78.57	21	70.00	95.45	0.18	8	23	17	9	51	
25	Dose1	86.15	49	72.06	87.50	0.21	7	21	15	15	74	
26	Dose1					•	•		•		•	
27	Dose1	84.48	34	55.74	69.39	0.20	6	20	16	14	36	
28	Dose1	87.10	25	51.02	92.59	0.21	6	19	18	7	58	
29	Dose1	86.96	12	46.15	60.00	0.19	. 6	20	17	17	45	
30	Dose1	87.50	25	41.67	89.29	0.19	7	23	19	-34	61	
31	Dose1	87.76	39	78.00	90.70	0.20	7	23	16	28	- 9	
32	Dose1	71.43	11	21.57	73.33	0.22	6	18	16	-26	22	
33	Dose1	62.16	15	23.44	65.22	0.20	6	22	16	23	24	
34	Dose1	94.12	26	56.52	81.25	0.19	6	20	15	18	27	
35	Dose1	85.37	28	60.87	80.00	0.20	7	20	16	11	59	
36	Dose1	71.64	40	59.70	83.33	0.19	6	21	16	3	49	
37	Dose1	93.18	21	46.67	51.22	0.17	6	19	16	12	55	
38	Dose1	•	•	•	•	•	•	•	•	•	•	
39	Dose1	•			•	•	•			•	• •	
40	Dose1	89.47	44	75.86	86.27	0.21	6	20	18	-6	28	
41	Dose2	• •	•	•	•	•	. •	•	•	•	•	
42	Dose2		•			•						
43	Dose2	85.37	23	37.10	65.71	0.21	7	24	18	9	42	
44	Dose2	92.45	44	80.00	89.80	0.21	7	21	16	19	50.	
45	Dose2	95.24	21	48.84	52.50	0.18	7	22	17	40	48	
46	Dose2	75.00	22	39.29	52.38	0.19 0.22	5 5	17 0	.14 15	11 3	44 23	
47		100.00	3	100.00 54.39	100.00 68.89	0.22	6	19	17	-18	23 35	
48	Dose2	81.82 81.25	31 19	57.58	73.08	0.20	7	21	16	20	44	
49 50	Dose2 Dose2	87.50	23	38.33	46.94	0.21	6	18	16	14	32	
51	Dose2	82.26	40	62.50	78.43	0.20	7	21	17.	30	47	
52	Dose2	95.65	16	40.00	72.73	0.19	6	23	16	- 7	0	
53	Dose2	97.83	37	77.08	82.22	0.21	6	22	17	7	20	
54	Dose2	85.71	39	60.94	72.22	0.21	. 6	23	16	9	52	
55	Dose2				,							
56	Dose2	81.97	22	35.48	44.00	0.20	6	19	16	10	58	
57	Dose2											
58	Dose2		0	•					13			
59	Dose2		27			0.19	6	20	17	6	38	
60	Dose2					•				•		
61	Dose3		0	0.00		0.21			15	•	•	
62	Dose3	93.94	12	25.53	38.71	0.19	7	22	16	9	25	
63	Dose3	71.43	0	0.00	0.00	0.20	5		16	19	- 9	
64	Dose3	-			•	•				•		
65	Dose3	78.00	27	49.09	69.23	0.19	6	20	14	4	27	
66	Dose3	•	•	•	.•	•	•		•		•	
67	Dose3	•		•	•	•	•	•	•	•	•	
68	Dose3	92.16	36	62.07	76.60	0.19	6	21	17	•	36	
69	Dose3		28		87.50	0.19		20	18	-7	55	
70	Dose3	86.21	18	58.06	72.00	0.20	6	19	16	17	20	
						D 01	C 4 =					

Page 24 of 45

PMRA Document ID: 1731030								EPA MRID Number: 47699904						
71	Dose3	91.18	20	58.82	64.52	0.19	6	20	14		•			
72.	Dose3	84.75	38	63.33	76.00	0.21	7	23	19	16	31			
73	Dose3	81.58	19	44.19	61.29	0.20	6	19	16	8	24			
74	Dose3	74.24	32	47.76	65.31	0.20	6	23	16	2	19			
75	Dose3	94.83	29	47.54	52.73	0.19	6	20	17	-8	48			
76	Dose3						• :	•			•			
77	Dose3			• .					٠.			•		
78	Dose3	66.67	, 5	14.71	50.00	0.17	6	19	17	3	-14			
79	Dose3	80.33	32	50.79	65.31	0.21	6	20	15	-2	45			
80	Doges													

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE EL (Eggs Laid)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Snapiro-Wilks	Snapiro-wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.887	<.001	2.241	0.094	USE NON-PARAMETRIC TESTS
•				
******	******	******	*******	********
BASIC SUMMARY S	TATISTICS	*		
Level N Me	ean StdDev	StdErr	Coef of Va	r 95% Conf.Interval

Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	58.20	16.66	4.30	28.63	48.97, 67.43
Dose1	16	61.75	10.96	2.74	17.75	55.91, 67.59
Dose2	15	54.33	23.67	6.11	43.57	41.22, 67.44
Dose3	14	53.07	22.17	5.92	41.77	40.27, 65.87
					•	
Level		Median	Min	Max	%of Control(means) %Reduction(means)
Ctrl		64.00	25.00	77.00	• • •	•
Dose1		61.50	39.00	80.00	106.10	-6.10
Dose2		65.00	1.00	77.00	93.36	6.64
Dose3		58.50	7.00	77.00	91.19	8.81

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

0.39 0.943

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	64.00		• •	
Dose1	61.50		1.000	0.547
Dose2	65.00		1.000	0.480
Dose3	58.50		1.000	0.336
SUMMARY		NOEC	LOEC) · · · · · · · · · · · · · · · · · · ·

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

MannWhit (Bonf adjust) Dose3 >highest dose Jonckheere Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE NEG EC (Eggs Cracked)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05

Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

Test Stat P-value

0.972 0.187 2.632 0.059 USE PARAMETRIC TESTS

BASIC ST	UMMAR	Y STATIST	rics				
Level	N .	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval	
Ctrl	15	3.07	2.15	0.56	70.23	1.87, 4.26	
Dose1	16	5.50	2.85	0.71	51.85	3.98, 7.02	
Dose2	15	2.13	1.51	0.39	70.57	1.30, 2.97	
Dose3	14	3.64	2.68	0.72	73.51	2.10, 5.19	
Level		Median	Min	Max	%of Control(means)	%Reduction(means)	
Ctrl		3.00	1.00	9.00	•		
Dose1		5.50	1.00	12.00	179.35	-79.35	
Dose2		2.00	0.00	5.00	69.57	30.43	
Dose3		3.50	0.00	7.00	118.79	-18.79	

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value
3 56 5.64 0.002

Dunnett - testing each trt mean signif. greater than control Williams - test assumes dose-response relationship, testing positive trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams			Tukey p-v	<i>r</i> alues	
	No.	p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	3.07		3.07		0.029	0.701	0.913		
Dose1	5.50	0.008	3.80	0.234		0.001	0.150		•
Dose2	2.13	0.972	3.80	0.255		•	0.322		• .
Dose3	3.64	0.472	3.80	0.269	•*	•		•	. •
SUMMAR	Y		NOEC		LOEC			. •	
Dunn	ett		<low< td=""><td>est dose</td><td>Dose1</td><td></td><td></td><td></td><td></td></low<>	est dose	Dose1				
Will	iams		Dose	:3	>highes	st dose			

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE ENC_EL ((EL-EC)/EL (%))

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030

EPA MRID Number: 47699904

0.14

TESTS	of	ASSUMPTIONS	FOR	PARAMETRIC	ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wi	lks Shar	oiro-Wilks	Levenes	Levenes	Conclusion
Test Sta	it P-	-value	Test Sta	it P-value	
0.465	<	<.001	1.730	0.171	USE NON-PARAMETRIC TESTS
******	******	******	******	******	********
BASIC SUMMAR	Y STATIST	TICS			
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl 15	93.94	5.76	1.49	6.13	90.75, 97.13
Dosel 16	90.29	6.84	1.71	7.58	86.65, 93.94
Dose2 15	90.06	25.02	6.46	27.78	76.20, 100.00
Dose3 14	93.81	4.88	1.30	5.20	91.00, 96.63
Level	Median	Min	Max	%of Control(me	eans) %Reduction(means)
Ctrl	96.10	80.00	98.61	•	
Dosel	92.02	73.91	98.08	96.12	3.88
Dose2	95.83	0.00	100.00	95.86	4.14

100.00

Jonckheere

Dose3

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

99.86

>highest dose

Kruskal-Wallis test - equality among treatment groups

84.44

Degrees of Freedom TestStat P-value

95.13

8.10

0.044

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level N	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	96.10		•	•
Dose1	92.02		0.059	0.015
Dose2	95.83		0.808	0.724
Dose3	95.13		1.000	0.692
SUMMARY MannWhit	(Bonf	NOEC adjust) Dose3	LOEC >highes	t dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE ES (Eggs Set)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Dose3

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.899	<.001	1.412	0.249	USE NON-PARAMETRIC TESTS

PMRA Submission Number: 2008-0430

Jonckheere

Dose3 14

PMRA Document ID: 1731030 EPA MRID Number: 47699904

		لله ملد بلد بلد بلد بلد بلد بلد			******		. + + + + + + + + + + + + + +

BASIC ST			7.7	a. 1-		~ .	
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.I	nterval
Ctrl	15	50.27	16.10	4.16	32.03	41.35,	59.18
Dose1	16	51.19	12.13	3.03	23.69	44.72,	57.65
Dose2	15	47.80	21.33	5.51	44.62	35.99,	59.61
Dose3	14	44.64	19.76	5.28	44.27	33.23,	56.05
Level	. 1	Median	Min	Max	%of Control(means) %Reduct	ion(means)
Ctrl		55.00	17.00	69.00	•		
Dose1		50.50	26.00	68.00	101.83	-1.8	3
Dose2		56.00	0.00	70.00	95.09	4.9	1
Dose3		51.00	4.00	67.00	88.81	11.1	.9
*****	*****	******	*****	****	******	*****	*****
NON-PARA	METRI	C ANALYS	ES - use	alpha-le	evel=0.05 for all	tests	
Krus	skal-W	allis te	st - equalit	y among	treatment groups		
Deg	grees	of Freed	lom TestSta	ıt P-	value		
	3		0.56	i,, (0.906		

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	55.00		1	-
Dose1	50.50	•	1.000	0.399
Dose2	56.00		1.000	0.480
Dose3	51.00		0.884	0.278
SUMMARY		NOEC	LOEC	
MannWhit	(Bonf	adjust) Dose3	>high	est dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15

Dose3

ANALYSIS RESULTS FOR VARIABLE ES_EL (EggsSet/EggsLaid (%))

81.75 8.69

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.552	<.001	1.393	0.254	USE NON-PARAMETRIC TESTS

>highest dose

BASIC SUMMARY STATISTICS StdErr Coef of Var 95% Conf.Interval Level N Mean StdDev 1.75 81.55, 89.08 Ctrl 15 85.32 6.80 7.97 7.28 1.82 78.10, 85.86 Dose1 16 81.98 8.88 Dose2 15 81.32 22.87 5.90 28.12 68.66, 93.98

2.32

Page 28 of 45

10.63

76.73,

86.77

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Level Ctrl	Median 87.50	Min 68.00	Max 90.28	%of Control(means)	%Reduction(means)
Dose1	84.75	65.22	89.33	96.09	3.91
Dose2	86.36	0.00	91.67	95.32	4.68
Dose3	83.45	57.14	90.00	95.82	4.18

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 6.24 0.100

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	87.50		•	•
Dosel	84.75		0.070	0.018
Dose2	86.36	,	1.000	0.512
Dose3	83.45		0.313	0.216

SUMMARY NOEC LOEC

MannWhit (Bonf adjust) Dose3 >highest dose
Jonckheere Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE VE (Viable Embryo(d14))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

obe parameters o	marybob ir more	ici cepe icj	ceca, cer	ciwibe non parametric	. anaryscs
Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion	
Test Stat	P-value	Test Stat	P-value		
0.944	0.008	0.796	0.501	USE NON-PARAMETRIC	TESTS

BASIC SUM	MARY STATIS'	TICS				
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval
Ctrl 1	5 47.60	15.96	4.12	33.53	38.76,	56.44
Dose1 1	6 44.25	14.10	3.52	31.86	36.74,	51.76
Dose2 1	5 44.60	21.13	5.46	47.38	32.90,	56.30
Dose3 1	39.36	20.02	5.35	50.86	27.80,	50.92
Level	Median	Min	Max	%of Control(means)	%Reduct	cion(means)
Ctrl	53.00	17.00	67.00	•		
Dose1	44.50	23.00	67.00	92.96	7.0)4
Dose2	54.00	0.00	64.00	93.70	6.3	30
Dose3	36.50	0.00	67.00	82.68	17.3	32

PMRA Submission Number: 2008-0430 PMRA Document ID: 1731030

Dose3

PMRA Document ID: 1731030	EPA MRID Number: 47699904

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 1.30 0.728

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWh	it(Bon a	adjust)p-value	Jonckl	neere p-value
Ctrl	53.00						•
Dose1	44.50			0.778			0.251
Dose2	54.00			1.000			0.420
Dose3	36.50		1	0.486			0.212
SUMMARY			NOEC		LOEC		
MannWhi	Lt (Bonf	adjust)	Dose3		>highes	t dose	
Jonckhe	eere		Dose3		>highes	t dose	

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE VE ES (ViableEmbryo/EggsSet (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.750	<.001	3.400	0.024	USE NON-PARAMETRIC TESTS

************************* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf.Interval Ctrl 15 94.74 7.96 2.06 8.41 90.33, 99.15 Dosel 16 86.73 17.66 4.42 20.37 77.32, 96.14 Dose2 14 93.32 12.56 3.36 13.46 86.07, 100.00 Dose3 14 81.95 26.64 7.12 32.51 66.56, 97.33 Min Max %of Control(means) %Reduction(means) Level Median 98.18 75.00 100.00 .
96.13 47.06 100.00 91.55
98.21 57.50 100.00 98.51
91.36 0.00 100.00 86.50 Ctrl Dose1 8.45 1.49 Dose2

13.50

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 5.52 0.137

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030		EPA MRID Number: 47699904

I MIKA DOC	unient ID. 1731	.030			EFAT	VIIII VIIIII	001.4/03330	<i>J</i> 4
					,			
Level	Median	MannWhit	(Bon adjust)p-value	Jonckh	eere p-va	lue	
Ctrl	98.18			-		•		
Dose1	96.13		0.348			0.107		•
Dose2	98.21		1.000			0.500		
Dose3	91.36		0.091			0.080		
SUMMARY		МО	EC	LOEC				
MannWh	nit (Bonf ad	iust) D	ose3	>highes	t dose			
Jonekl		•	ose3	>highes				
				5				
Bobwhite	quail repro	. Saflufena	cil. MRID 4	71279-15				
	RESULTS FOR)			
	11200230 1011		_ (,			
TESTS OF	ASSUMPTIONS	FOR PARAME	TRIC ANALVS	TS		•		
	Vilks test f			- ·	a_lawal.	-0.01	į.	
	test for home						-level-h	05
	metric analy							
		ses II NeIC piro-Wilks	Levenes	Levenes	.erwise .Concl		letite alla	түрер
Test		pilo-wilks -value	Test Stat		COLICI	usion		
					TIGE D	ARAMETRIC		
0.5	949	0.014	0.755	0.524	USE P.	ARAMETRIC	. TESIS	
*****	*****	++++++++++			****	*****		. + +
	MMARY STATIS				****			
Level 1			StdErr	Coef of V	·	5% Conf.I	ntomial	
Ctrl 1		16.06	4.15	34.57	ar 9	37.57,	55.36	
Dose1				33.92		•		
		14.46	3.61			34.92,	50.33	
Dose2		20.78	5.36	47.51		32.23,	55.24	•
Dose3	14 38.21	20.64	5.52	54.01		26.30,	50.13	
				/	,			,
Level	Median	Min		of Control(means)	*Reduct	ion(means	;)
Ctrl	53.00	17.00	66.00	•		•		
Dose1	41.00	21.00	67.00	91.73		8.2		
Dose2	53.00	0.00	63.00	94.12		5.8	18	
Dose3	36.00	0.00	66.00	82.24		17.7	'6	
*****	*****	*****	*****	******	*****	******	*****	**
PARAMETR:	IC ANALYSES	- use al	pha-level=0	.05 for all	tests			
Analy	ysis of Vari	ance (ANOVA	.) - overall	F-test				
Nume	erator df	Denominato	r df F-s	tat P	-value	•		
	3	56	0.	52 0	.671			
								4
Dunnett -	- testing ea	ch trt mean	signif. le	ss than con	trol		* 1	
	- test assu					negative	trend	
	two-sided te							
· · · · · · · · · · · · · · · · · · ·		,					· · ;	

Level		Mean	Dunnett	Isotonic	Williams			Tukey p-	values	
			p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
	Ctrl	46.47		46.47		0.934	0.976	0.612		•
	Dose1	42.63	0.502	43.16	0.365	•	0.998	0.909		•
	Dose2	43.73	0.581	43.16	0.394	•		0.844	•	
	Dose3	38.21	0.241	38.21	0.147				.	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

SUMMARY NOEC . LOEC

Dunnett Dose3 >highest dose
Williams Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15
ANALYSIS RESULTS FOR VARIABLE LE_VE (LiveEmbryo/ViableEmbryo (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance (absolute residuals) -- alpha-level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

Test Stat P-value Test Stat P-value

0.659 <.001 3.700 0.017 USE NON-PARAMETRIC TESTS

BASIC ST	UMMARY	STATIS	TICS		•	
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	97.23	4.25	1.10	4.37	94.88, 99.58
Dose1	16	96.05	6.52	1.63	6.79	92.58, 99.53
Dose2	14	98.19	2.33	0.62	2.38	96.84, 99.54
Dose3	13	94.65	11.36	3.15	12.00	87.78, 100.00
Level		Median	Min	Max	%of Control(means)	%Reduction(means)
Ctrl		100.00	84.62	100.00	•	•
Dose1		97.81	75.51	100.00	98.79	1.21
Dose2		98.43	91.11	100.00	100.99	-0.99
Dose3		98.51	62.50	100.00	97.35	2.65

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 0.50 0.919

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit (Bor	ı adjust)p-v	alue Joncki	neere p-value
Ctrl	100.00		•		•
Dose1	97.81		1.000		0.384
Dose2	98.43		1.000		0.569
Dose3	98.51		1.000		0.631
<i>.</i> *					
SUMMARY		NOEC	L	DEC	
MannWhit	(Bonf	adjust) Dose3	:	>highest dose	

Dose3

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE NH (Number Hatched)

Jonckheere

>highest dose

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion	
Test Stat	P-value	Test Stat	P-value		
0.943	0.007	0.372	0.773	USE NON-PARAMETRIC	TESTS
******	*****	*****	*****	******	******
BASTO STIMMARY ST	יאידפידרפ ^י				

BASIC ST	UMMARY	Z STATIS	TICS			
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	39.73	15.17	3.92	38.19	31.33, 48.14
Dose1	16	35.94	12.74	3.18	35.44	29.15, 42.72
Dose2	15	38.07	17.91	4.62	47.05	28.15, 47.99
Dose3	14	32.43	17.52	4.68	54.03	22.31, 42.55
Level		Median	Min	Max	%of Control(means) %Reduction(means)
Ctrl		41.00	15.00	60.00	•	
Dosel		35.00	15.00	56.00	90.45	9.55
Dose2		45.00	0.00	60.00	95.81	4.19
Dose3		31.50	0.00	55.00	81.62	18.38

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value 3 1.92 0.588

MannWhit(Bon) - testing each trt median signif. less than control

Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p	-value 3	Jonckhe	ere p-	value
Ctrl	41.00		•				
Dose1	35.00		0.653		C	.209	
Dose2	45.00		1.000		C	.484	
Dose3	31.50		0.359		C	.206	
SUMMARY MannWhit Jonckhee		NOEC adjust) Dose3		LOEC >highest >highest			

Bobwhite quail repro, Saflufenacil, MRID 471279-15
ANALYSIS RESULTS FOR VARIABLE NH EL (NumberHatched/EggsLaid (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.846	<.001	0.836	0.480	USE NON-PARAMETRIC TESTS

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA	MRID Number: 47699904
-------------------------------	-----------------------

					******	Stantantantantantantantanta
BASIC SUMMA			*****	. * * * * * * * * * * * * * * * * * * *	******	*****
Level N		StdDev	StdErr	Coef of Var	95% Conf.Inte	rval
Ctrl 15	66.96	12.49	3.23	18.66		.88
Dosel 16			4.08	28.13	•	.64
Dose2 15	65.58		5.31	31.36		.97
Dose3 14	55.28	21.77	5.82	39.38	•	.85
Level	Median	Min	Max %	of Control(mea	ans) %Reduction	(means)
Ctrl	65.63	36.17	85.29			(
Dose1	62.59	25.00	78.13	86.54	13.46	
Dose2	72.22	0.00	80.36	97.93	2.07	
Dose3	63.27	0.00	75.34	82.56	17.44	•
*******	*****	*****	****	****	*****	****
NON-PARAMET				rel=0.05 for all		
			-	reatment group		
	s of Free	_	_		,	
Degree	3			076		
	3 .	0.	0.	070		
Manawhit /Pc	m) - teat	ing each tr	t median di	gnif. less tha	an control	
		_		_	esting negative t	rond
DOMERMEETE	- test as:	sumes dose-	respoitse re	:Lacionship, ce	sacing negacive c	rena
Level	Median	MannWhit.	(Bon adjust	n-value Jo	onckheere p-value	
Ctrl	65.63	110111111111111111111111111111111111111	(Don adjube	.,p (a1ac o	Juliania p varao	
	62.59		0.256		0.077	
Dose2	72.22		1.000		0.686	
Dose3	63.27		0.251		0.190	
DODED	03.27		0.232		,	
SUMMARY		NO	EC	LOEC		
	: (Bonf ad	iust) D	ose3	>highest o	lose	
Jonckhee	_		ose3	>highest		
		_		· J		
Bobwhite au	ail repro	, Saflufena	cil, MRID 4	71279-15		
_	-			berHatched/Egg	rsSet (%))	
			. –	, , 5,	, , , ,	
TESTS OF AS	SUMPTIONS	FOR PARAME	TRIC ANALYS	SIS		
				als alpha-1	level=0.01	
					uals) alpha-le	vel=0.05
					vise non-parametr	
Shapiro-W		piro-Wilks	Levenes		Conclusion	
Test St		value	Test Stat	_		
0.897		<.001	2.082		JSE NON-PARAMETRI	C TESTS
0.037			2.002			0 12010
*****	****	*****	******	*****	******	*****
BASIC SUMMA	RY STATIST	rics				
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Inte	rval
Ctrl 15	78.24	12.32	3.18	15.75		.06
Dosel 16	70.94	19.13	4.78	26.97	· ·	.13
Dose2 14	80.87	12.69	3.39	15.69	· · · · · · · · · · · · · · · · · · ·	.19
Dose3 14	65.77	25.23	6.74	38.36	· ·	.34
PODCO II	,00.77	20.20	0.7.2	55.55	22.20, 00	

PMRA Document ID: 1731030	•	EPA MRID Number: 47699904

Level	Median	Min	Max	<pre>%of Control(means)</pre>	%Reduction(means)
Ctrl	75.00	51.52	95.08	•	•
Dose1	76.51	29.41	91.11	90.67	9.33
Dose2	81.16	55.00	100.00	103.36	-3.36
Dose3	72.61	0.00	91.18	84.07	15.93

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 4.59 0.205

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	75.00		•	•
Dose1	76.51		1.000	0.215
Dose2	81.16		1.000	0.748
Dose3	72.61	`	0.291	0.234

SUMMARY NOEC LOEC

MannWhit (Bonf adjust) Dose3 >highest dose Jonckheere Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE NH_LE (NumberHatched/LiveEmbryo (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.950	0.018	0.303	0.823	USE PARAMETRIC TESTS

BASIC ST	JMMARY	STATIST	ICS			
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15 '	84.67	8.51	2.20	10.06	79.96, 89.39
Dose1	16	83.99	8.80	2.20	10.47	79.30, 88.68
Dose2	14	88.38	7.63	2.04	8.63	83.97, 92.78
Dose3	13	83.80	9.36	2.59	11.16	78.15, 89.45
Level	1	Median	Min	Max	%of Control (means)	%Reduction(means)
Ctrl		82.81	70.37	96.67	en e	or the contract of the contra
Dose1		86.56	62.16	94.12	99.19	0.81
Dose2		86.61	75.00	100.00	104.37	-4.37
Dose3		84.75	66.67	94.83	98.97	1.03

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030

EPA MRID Number: 47699904

Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 0.88 . 3 54 0.458

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams		r	Tukey p-v	<i>r</i> alues	
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	84.67	•	85.58	•	0.996	0.654	0.993		•
Dose1	83.99	0.667	85.58	0.703	•	0.507	1.000		•
Dose2	88.38	0.978	85.58	0.734			0.515	•	•.
Dose3	83.80	0.648	83.80	0.514	•	•	•	•	•
SUMMARY Dunne Willi	tt		NOEC Dose Dose	-	_	st dose st dose			

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE HS (Hatching Survival(d14))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.964	0.074	0.216	0.885	USE PARAMETRIC TESTS

BASIC SUMMARY STATISTICS

DADIC DO	71.11.17	CI DIMITO	1100				
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval	
Ctrl	15	27.60	12.82	3.31	46.46	20.50, 34.70	
Dosel	16	27.63	11.28	2.82	40.85	21.61, 33.64	
Dose2	15	24.47	12.62	3.26	51.58	17.48, 31.46	
Dose3	14	21.14	12.82	3.43	60.65	13.74, 28.55	
Level		Median	Min	Max	%of Control (means)) %Reduction(means)	,
Ctrl		32.00	5.00	43.00		•	
Dosel		25.50	11.00	49.00	100.09	-0.09	
Dose2		23.00	0.00	44.00	88.65	11.35	
Dose3		23.50	0.00	38.00	76.60	23.40	

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test Numerator df Denominator df F-stat P-value 56 0.91

Dunnett - testing each trt mean signif. less than control

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams	Tukey p-values				
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	27.60	•	27.61	•	1.000	0.899	0.502	•	•
Dose1	27.63	0.752	27.61	0.585	•	0.893	0.486	•	
Dose2	24.47	0.456	24.47	0.314	•	•	0.888	, •	
Dose3	21.14	0.185	21.14	0.107	•		•		•
SUMMARY Dunne Will:	ett		NOEC Doses Doses	•	_	st dose st dose			

Bobwhite quail repro, Saflufenacil, MRID 471279-15
ANALYSIS RESULTS FOR VARIABLE HS ES (HatchingSurvival/EggsSet (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	· .
0.975	0.259	0.964	0.416	USE PARAMETRIC TESTS

BASIC ST	JMMARY	STATIST	ICS				
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Int	erval
Ctrl	15	52.65	15.01	3.87	28.50	44.34,	50.96
Dose1	16	54.00	16.41	4.10	30.38	45.26,	52.74
Dose2	14	55.01	19.60	5.24	35.64	43.69,	6.32
Dose3	14	40.73	21.76	5.82	53.43	28.16,	3.29
Level		Median	Min	Max	%of Control(means)	%Reduction	on(means)
Ctrl		52.94	18.52	70.49	•		* -
Dose1		56.13	21.57	78.00	102.57	-2.57	
Dose2		51.61	35.48	100.00	104.47	-4.47	
Dose3		48.02	0.00	63.33	77.35	22.65	

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value
3 55 1.88 0.143

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level Mean Dunnett Isotonic Williams Tukey p-values $p\text{-value} \quad \text{mean} \quad p\text{-value} \quad \text{Dose1} \quad \text{Dose2} \quad \text{Dose3} \quad \text{Dose4} \quad \text{Dose5}$ $Page \ 37 \ of \ 45$

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030	EPA MRID Number: 47699904

Ctrl	52.65	•	53.86		0.997	0.985	0.305			
Dose1	54.00	0.820	53.86	0.660	•	0.999	0.206		•	
Dose2	55.01	0.859	53.86	0.693		•	0.176	•	•	
Dose3	40.73	0.101	40.73	0.053	• •	•	-	•	••	
SUMMARY Dunne Willi	ett		NOEC Dose3 Dose3		_	est dose				

Bobwhite quail repro, Saflufenacil, MRID 471279-15
ANALYSIS RESULTS FOR VARIABLE HS NH (HatchingSurvival/NumberHatched (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.946	0.012	0.338	0.798	USE PARAMETRIC TESTS

BASIC ST	JMMAR	Y STATIST	rics			
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	67.26	16.16	4.17	24.02	58.31, 76.20
Dose1	16	76.67	13.93	3.48	18.17	69.24, 84.09
Dose2	14	67.42	17.34	4.64	25.72	57.41, 77.43
Dose3	13	59.94	21.99	6.10	36.68	46.65, 73.22
Level		Median	Min	Max	%of Control(means)	%Reduction(means)
Ctrl		69.05	25.00	88.24		
Dose1		80.63	51.22	95.45	113.99	-13.99
Dose2		70.56	44.00	100.00	100.25	-0.25
Dose3		65.31	0.00	87.50	89.12	10.88

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value

Numerator df Denominator df F-stat P-value
3 54 2.27 0.090

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams	Tukey p-values				
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	67.26	•	72.11	•	0.440	1.000	0.683		
Dose1	76.67	0.992	72.11	0.857	•	0.471	0.059	•	
Dose2	67.42	0.763	67.42	0.629	•	•	0.679	•	
Dose3	59.94	0.284	59.94	0.178	-	•	•	•	•

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

SUMMARY NOEC LOEC

Dunnett Dose3 >highest dose Williams Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE THICK (Eggshell thickness)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion	
Test Stat	P-value	Test Stat	P-value		
0.982	0.520	0.620	0.605	USE PARAMETRIC	TESTS

***	****	****	****	*****	*******	******	*****
BASIC ST	UMMARY	STATIS	TICS				
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval
Ctrl	15	0.20	0.01	0.00	5.67	0.19,	0.21
Dose1	16	0.20	0.01	0.00	6.41	0.19,	0.20
Dose2	14	0.20	0.01	0.00	5.88	0.20,	0.21
Dose3	14	0.20	0.01	0.00	5.57	0.19,	0.20
Level]	Median	Min	Max	%of Control(means)	%Reduct	tion(means)
Ctrl		0.20	0.18	0.23	•		

Ctrl	0.20	0.18	0.23	•	
Dose1	0.20	0.17	0.22	98.12	1.88
Dose2	0.20	0.18	0.22	101.07	-1.07
Dose3	0.20	0.17	0.21	97.86	2.14

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Analysis of Variance (ANOVA) - overall F-test

Williams

Numerator df Denominator df F-stat P-value 3 55 0.99 0.403

Dose3

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams			Tukey p-	values	
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	0.20	•	0.20		0.810	0.961	0.759	•	•
Dose1	0.20	0.371	0.20	0.480		0.521	0.999	•	•
Dose2	0.20	0.893	0.20	0.515		•	0.474		
Dose3	0.20	0.333	0.20	0.217	•	•	•	•	
SUMMARY Dunne			NOEC Dose	3	LOEC >highe	st dose			

>highest dose

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE HATWT (Hatchling Weight)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.986	0.760	0.606	0.614	USE PARAMETRIC TESTS

*****	***	*****	******	******	*******	*******
BASIC S	UMMA	RY STATIST	rics			
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	6.61	0.38	0.10	5.68	6.40, 6.81
Dose1	16	6.44	0.54	0.14	8.44	6.15, 6.73
Dose2	14	6.25	0.54	0.14	8.67	5.94, 6.56
Dose3	13	5.98	0.44	0.12	7.39	5.71, 6.24
Level		Median	Min	Max	%of Control(means)	%Reduction(means)
Ctrl		6.60	5.80	7.10	•	•
Dose1		6.25	5.70	7.60	97.53	2.47
Dose2		6.35	5.00	7.00	94.60	5.40
Dose3		6.10	5.00	6.60	90.47	9.53

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Analysis of Variance (ANOVA) - overall F-test

Numerator df Denominator df F-stat P-value 3 54 4.39 0.008

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Williams			Tukey p-	values	
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	6.61		6.61	•	0.784	0.205	0.006		
Dose1	6.44	0.352	6.44	0.210	•	0.693	0.058	•	
Dose2	6.25	0.065	6.25	0.031			0.463		. •
Dose3	5.98	0.002	5.98	<.001		•	•	• .	•
SUMMARY			NOEC		LOEC	•			
Dunne Willi			Dose:		Dose3 Dose2				
				_					

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE SURVWT (Survivor Wt (d14))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

Levenes test for	or homogeneity of	variance(absolute	residuals)	alpha-level	-0.05
Use parametric	analyses if neit	her test rejected,	otherwise r	non-parametric	analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.663	<.001	2.386	0.079	USE NON-PARAMETRIC TESTS

BASIC SUMMAR	RY STATIST	rics				
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval	
Ctrl 15	21.43	1.69	0.44	7.87	20.49, 22.36	
Dosel 16	20.83	1.80	0.45	8.62	19.87, 21.78	
Dose2 14	19.24	5.90	1.58	30.67	15.84, 22.65	
Dose3 12	20.40	1.44	0.41	7.04	19.49, 21.31	
Level	Median	Min	Max	%of Control(means) %Reduction(means)	
Ctrl	21.00	18.30	24.80	•	· · · · · · · · ·	
Dose1	20.60	17.50	23.90	97.19	2.81	
Dose2	20.60	0.00	24.20	89.81	10.19	
Dose3	20.10	18.50	23.30	95.21	4.79	

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat D value

Degrees of Freedom TestStat P-value 3 2.71 0.438

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	21.00		•	•
Dose1	20.60		0.687	0.220
Dose2	20.60		0.385	0.119
Dose3	20.10		0.163	0.060

SUMMARY NOEC LOEC

MannWhit (Bonf adjust) Dose3 >highest dose
Jonckheere Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE FOOD (Food Consumption)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion
Test Stat P-value Test Stat P-value

0.987 0.781 0.300 0.825 USE PARAMETRIC TESTS

BASIC SUMMARY STATISTICS

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030		EPA MRID Number: 47699904
---------------------------	--	---------------------------

Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval
Ctrl	15	15.87	0.89	0.23	5.62	15.38, 16.37
Dose1	16	16.53	1.04	0.26	6.31	15.97, 17.08
Dose2	15	16.06	1.30	0.34	8.12	15.34, 16.78
Dose3	14	16.18	1.35	0.36	8.31	15.40, 16.96
Level		Median	Min	Max	%of Control(means)	%Reduction(means)
Ctrl		16.00	14.50	17.40		
Dose1		16.25	14.90	18.50	104.11	-4.11
Dose2		16.20	12.50	18.00	101.18	-1.18
Dose3		16.00	14.10	18.80	101.92	-1.92

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Analysis of Variance (ANOVA) - overall F-test

Numerator df Denominator df F-stat P-value
3 56 0.88 0.458

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean	Dunnett	Isotonic	Isotonic Williams		Tukey p-values					
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5		
Ctrl	15.87		16.21		0.404	0.971	0.892				
Dose1	16.53	0.993	16.21	0.864	•	0.679	0.845				
Dose2	16.06	0.881	16.12	0.832		•	0.993	•			
Dose3	16.18	0.931	16.12	0.846	• .	•	-	•	•		
SUMMARY	Y		NOEC		LOEC						
Dunne	ett		Dose	:3	>highe	st dose					
Will:	iams		Dose	:3	>highe	st dose					

Bobwhite quail repro, Saflufenacil, MRID 471279-15
ANALYSIS RESULTS FOR VARIABLE WTGAINM (Male wt gain)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.939	0.007	1.515	0.222	USE NON-PARAMETRIC TESTS

STATIS'	TICS				
Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval
5.76	22.39	5.78	388.72	-6.64,	18.16
6.76	16.44	4.11	243.06	-2.00,	15.52
10.92	14.11	3.77	129.24	2.77,	19.07
5.54	9.31	2.81	168.20	-0.72,	11.79
	Mean 5.76 6.76 10.92	5.76 22.39 6.76 16.44 10.92 14.11	Mean StdDev StdErr 5.76 22.39 5.78 6.76 16.44 4.11 10.92 14.11 3.77	Mean StdDev StdErr Coef of Var 5.76 22.39 5.78 388.72 6.76 16.44 4.11 243.06 10.92 14.11 3.77 129.24	Mean StdDev StdErr Coef of Var 95% Conf. 5.76 22.39 5.78 388.72 -6.64, 6.76 16.44 4.11 243.06 -2.00, 10.92 14.11 3.77 129.24 2.77,

Page 42 of 45

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030	•	EPA MRID Number: 47699904

Level	Median	Min	Max	%of Control(means)	%Reduction(means)
Ctrl	9.00	-50.10	35.60	•	• • • • • • • • • • • • • • • • • • •
Dose1	11.05	-34.10	28.10	117.40	-17.40
Dose2	9.35	-17.80	39.60	189.61	-89.61
Dose3	4.30	-7.80	19.30	96.12	3.88

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 1.69 0.639

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	9.00			•
Dose1	11.05		1.000	0.524
Dose2	9.35		1.000	0.646
Dose3	4.30		0.809	0.276

SUMMARY NOEC LOEC

MannWhit (Bonf adjust) Dose3 >highest dose
Jonckheere Dose3 >highest dose

Bobwhite quail repro, Saflufenacil, MRID 471279-15 ANALYSIS RESULTS FOR VARIABLE WTGAINF (Female wt gain)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.965	0.095	1.645	0.190	USE PARAMETRIC TESTS

BASIC SUMM	ARY STATIS	TICS		1		
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Int	erval
Ctrl 15	31.91	11.62	3.00	36.41	25.48, 3	88.35
Dosel 16	39.93	21.27	5.32	53.28	28.59,	51.27
Dose2 14	38.04	15.25	4.08	40.10	29.23, 4	16.85
Dose3 12	25.48	20.72	5.98	81.34	12.31,	38.64
Level	Median	Min	Max	%of Control(means) %Reduction	on(means)
Ctrl	32.60	15.20	51.70	•		
Dose1	44.55	-8.60	74.30	125.12	-25.12	
Dose2	43.30	0.40	57.60	119.21	-19.21	
Dose3	26.00	-14.20	54.50	79.83	20.17	

PMRA Submission Number: 2008-0430

PMRA Document ID: 1731030 EPA MRID Number: 47699904

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Analysis of Variance (ANOVA) - overall F-test

Numerator df Denominator df F-stat P-value 3 53 1.85 0.149

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOEC or LOEC

Level	Mean Dunnett		: Isotonic Willi		iams Tukey p-values							
		p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Doses	5		
Ctrl	31.91	•	36.67	•	0.588	0.785	0.781					
Dose1	39.93	0.984	36.67	0.850		0.991	0.151					
Dose2	38.04	0.961	36.67	0.872		-	0.278	•				
Dose3	25.48	0.352	25.48	0.231	•	٠	•	•	•			
SUMMARY Dunne Willi	tt		NOEC Dose	3	LOEC >highe Dose3	st dose		>hi	.ghest	dose		

Data Evaluation Report on the Reproductive Effects of BAS 800 H (Saflufenacil) on Northern Bobwhite (*Colinus virginianus*)



